Parkinson's disease is most commonly treated with levodopa, but the benefits wear off as the disease progresses and high doses can result in dyskinesia, which are involuntary and uncontrollable movements. To better understand the underlying reasons behind these effects, researchers created a model of the interactions between levodopa, dopamine, and the basal ganglia, an area of the brain that plays a crucial role in Parkinson's disease.